At the time of writing, Autolus Therapeutics plc ADR [AUTL] stock is trading at $1.75, saw in change for the day. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AUTL shares have gain 14.38% over the last week, with a monthly amount glided 24.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Autolus Therapeutics plc ADR [NASDAQ: AUTL] stock has seen the most recent analyst activity on November 18, 2024, when Goldman upgraded its rating to a Buy and also boosted its price target to $7.60 from $7. Previously, Redburn Atlantic upgraded its rating to Buy on November 15, 2024, and kept the price target unchanged to $13. On November 09, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $10 on the stock. Bryan Garnier initiated its recommendation with a Buy and recommended $5 as its price target on March 17, 2023. Jefferies upgraded its rating to Buy for this stock on June 14, 2021, and upped its price target to $12. In a note dated January 29, 2021, JP Morgan downgraded an Neutral rating on this stock but restated the target price of $9.
For the past year, the stock price of Autolus Therapeutics plc ADR fluctuated between $1.11 and $5.00. Currently, Wall Street analysts expect the stock to reach $8.87 within the next 12 months. Autolus Therapeutics plc ADR [NASDAQ: AUTL] shares were valued at $1.75 at the most recent close of the market. An investor can expect a potential return of 406.86% based on the average AUTL price forecast.
Analyzing the AUTL fundamentals
According to Autolus Therapeutics plc ADR [NASDAQ:AUTL], the company’s sales were 9.01M for trailing twelve months, which represents an -10.99% plunge. Gross Profit Margin for this corporation currently stands at -2.72% with Operating Profit Margin at -29.73%, Pretax Profit Margin comes in at -26.01%, and Net Profit Margin reading is -26.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.53 and Total Capital is -0.39. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7000 points at the first support level, and at 1.6500 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7900, and for the 2nd resistance point, it is at 1.8300.
Ratios To Look Out For
It is important to note that Autolus Therapeutics plc ADR [NASDAQ:AUTL] has a current ratio of 9.21. As well, the Quick Ratio is 8.99, while the Cash Ratio is 1.44. Considering the valuation of this stock, the price to sales ratio is 51.69, the price to book ratio is 1.26.
Transactions by insiders
Recent insider trading involved Martin Pule, Officer, that happened on Sep 16 ’24 when 0.7 million shares were purchased.
